BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

24 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.EBI
Eli Lilly
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).EBI
Amgen
Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2.EBI
Dart Neuroscience
Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.EBI
Glaxosmithkline
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.EBI
Cellzome
A quantitative analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
Comprehensive analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.EBI
Institute
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.EBI
Eli Lilly and Company
Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.EBI
The Scripps Research Institute
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator.EBI
Pharmaron UK Ltd.
Triazole-fused pyrimidines in target-based anticancer drug discovery.EBI
Zhenzhou University
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.EBI
Rapt Therapeutics
Discovery of 4EBI
TBA
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.EBI
Vertex Pharmaceuticals
NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDSBDB
Inflazome
Combination therapy comprising JAK pathway inhibitor and rock inhibitorBDB
Incyte
Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interactionBDB
H. Lee Moffitt Cancer Center and Research Institute
Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereofBDB
Shanghai Institute of Materia Medica
SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOFBDB
The Broad Institute
ASK1 inhibitor and preparation method and use thereofBDB
Fuijan Cosunter Pharmaceutical
Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseasesBDB
University of Washington Through Its Center For Commercialization
Compounds that are ERK inhibitorsBDB
Merck Sharp & Dohme